CHICAGOGefitinib (Iressa) produced clinically
meaningful improvement in disease-related symptoms in advanced non-small-cell
lung cancer (NSCLC), David F. Cella, PhD, reported at the 39th Annual Meeting
of the American Society of Clinical Oncology (abstract 2531). Dr. Cella is
professor, Northwestern University, and director, Center on Outcomes, Research
and Education (CORE), Evanston Northwestern Health-care, Evanston, Illinois.
The study was supported by AstraZeneca.